Corporate Members
The Pennsylvania Society of Oncology and Hematology expresses its gratitude to our corporate members. Donations from the following companies help us in fulfilling our mission.
To learn more about becoming a Corporate Member, please click here.
To learn more about becoming a Corporate Member, please click here.
10k Members
Bristol Myers Squibb
About Us:
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. We combine the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company powered by talented individuals who drive scientific innovation. We are proud of the advancements we have made in oncology, hematology, immunology and cardiovascular disease, and we are dedicated to helping patients prevail over serious diseases through our diverse and promising pipeline and new scientific platforms. We are pursuing therapies at the forefront of scientific discovery with the goal of bringing an exciting new generation of life-changing treatments to patients. We aspire to be at the center of a vibrant healthcare innovation ecosystem, where academic research centers, biotech and biopharma companies all contribute to continued scientific advancement. During this unprecedented time, if you have U.S. patients who have lost jobs and health insurance due to COVID-19, we will offer our covered medicines at no cost. For a complete list of our covered medicines, patients can call 1-800-721-8909 or visit www.bms.com to learn more.
Website:
www.bms.com
Representative Contacts:
Patrick Curtin, Patrick.Curtin@bms.com, 908-420-7093
Social Media:
Twitter: https://twitter.com/BMSNEWS
LinkedIn: https://www.linkedin.com/company/bristol-myers-squibb/
Instagram: https://www.instagram.com/bristolmyerssquibb/
Facebook: https://www.facebook.com/BristolMyersSquibb
YouTube: https://www.youtube.com/bristolmyerssquibb
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. We combine the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company powered by talented individuals who drive scientific innovation. We are proud of the advancements we have made in oncology, hematology, immunology and cardiovascular disease, and we are dedicated to helping patients prevail over serious diseases through our diverse and promising pipeline and new scientific platforms. We are pursuing therapies at the forefront of scientific discovery with the goal of bringing an exciting new generation of life-changing treatments to patients. We aspire to be at the center of a vibrant healthcare innovation ecosystem, where academic research centers, biotech and biopharma companies all contribute to continued scientific advancement. During this unprecedented time, if you have U.S. patients who have lost jobs and health insurance due to COVID-19, we will offer our covered medicines at no cost. For a complete list of our covered medicines, patients can call 1-800-721-8909 or visit www.bms.com to learn more.
Website:
www.bms.com
Representative Contacts:
Patrick Curtin, Patrick.Curtin@bms.com, 908-420-7093
Social Media:
Twitter: https://twitter.com/BMSNEWS
LinkedIn: https://www.linkedin.com/company/bristol-myers-squibb/
Instagram: https://www.instagram.com/bristolmyerssquibb/
Facebook: https://www.facebook.com/BristolMyersSquibb
YouTube: https://www.youtube.com/bristolmyerssquibb
Daiichi-Sankyo
About us:
The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by our DXd antibody drug conjugate (ADC) technology, our powerful research engines include biologics, medicinal chemistry, modality and other research laboratories in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA. For more information, please visit: www.DSCancerEnterprise.com.
Website:
www.DSCancerEnterprise.com ; www.dsi.com
Representative Contact:
Dan Pagana, dpagana@dsi.com, 570-974-1860
Social Media:
Twitter: https://twitter.com/DaiichiSankyoUS
LinkedIn: https://www.linkedin.com/company/daiichi-sankyo/
The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by our DXd antibody drug conjugate (ADC) technology, our powerful research engines include biologics, medicinal chemistry, modality and other research laboratories in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA. For more information, please visit: www.DSCancerEnterprise.com.
Website:
www.DSCancerEnterprise.com ; www.dsi.com
Representative Contact:
Dan Pagana, dpagana@dsi.com, 570-974-1860
Social Media:
Twitter: https://twitter.com/DaiichiSankyoUS
LinkedIn: https://www.linkedin.com/company/daiichi-sankyo/
Immunomedics
About Us:
Immunomedics is a leader in next generation antibody-drug conjugate (ADC) technology, committed to helping transform the lives of people with hard-to-treat cancers.
Website:
https://www.immunomedics.com/
Representatives:
Rep contact:
Stephen Gardner, Oncology Account Manager: Sgardner@immunomedics.com 412 2160075
Director of National Accounts:
Nicole Cornett: NCornett@immunomedics.com 2013414605
Social Media:
LinkedIn: https://www.linkedin.com/company/immunomedics/
Facebook: https://www.facebook.com/immunomedics/
Twitter: https://twitter.com/ImmunomedicsInc
Immunomedics is a leader in next generation antibody-drug conjugate (ADC) technology, committed to helping transform the lives of people with hard-to-treat cancers.
Website:
https://www.immunomedics.com/
Representatives:
Rep contact:
Stephen Gardner, Oncology Account Manager: Sgardner@immunomedics.com 412 2160075
Director of National Accounts:
Nicole Cornett: NCornett@immunomedics.com 2013414605
Social Media:
LinkedIn: https://www.linkedin.com/company/immunomedics/
Facebook: https://www.facebook.com/immunomedics/
Twitter: https://twitter.com/ImmunomedicsInc
Janssen
Merck
Social Media:
LinkedIn: linkedin.com/company/Merck
Facebook: www.facebook.com/Merckinvents
Twitter: twitter.com/Merck
Instagram: instagram.com/Merck
YouTube: youtube.com/user/Merck
LinkedIn: linkedin.com/company/Merck
Facebook: www.facebook.com/Merckinvents
Twitter: twitter.com/Merck
Instagram: instagram.com/Merck
YouTube: youtube.com/user/Merck
Oncopeptides
About us:
Oncopeptides was established solely to develop therapies for difficult-to-treat hematological diseases, and we are committed to bringing patients the treatments they need and the hope they deserve.
Websites:
https://www.oncopeptides.com/en
https://www.pepaxtohcp.com/
Representatives:
Sharon Maffei, Oncology Account Manager
Sharon.maffei@oncopeptides.com
570-357-6627
Nancy Ramos, Oncology Account Manager
Nancy.ramos@oncopeptides.com
917-494-4631
Oncopeptides was established solely to develop therapies for difficult-to-treat hematological diseases, and we are committed to bringing patients the treatments they need and the hope they deserve.
Websites:
https://www.oncopeptides.com/en
https://www.pepaxtohcp.com/
Representatives:
Sharon Maffei, Oncology Account Manager
Sharon.maffei@oncopeptides.com
570-357-6627
Nancy Ramos, Oncology Account Manager
Nancy.ramos@oncopeptides.com
917-494-4631
Seagen Inc.
About Us:
Seagen Inc. is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. We are leveraging our expertise in antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials for hematologic malignancies and solid tumors. For more information, visit www.seagen.com.
Click here to learn more.
Website:
www.seagen.com; https://www.seagen.com/medicines
Social Media:
LinkedIn: https://www.linkedin.com/company/seagen
Twitter: https://twitter.com/seagenglobal
Seagen Inc. is a global biotechnology company that discovers, develops, and commercializes medicines for cancer. The company has a pipeline of therapies at various stages of preclinical testing, clinical testing, and development. We are leveraging our expertise in antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials for hematologic malignancies and solid tumors. For more information, visit www.seagen.com.
Click here to learn more.
Website:
www.seagen.com; https://www.seagen.com/medicines
Social Media:
LinkedIn: https://www.linkedin.com/company/seagen
Twitter: https://twitter.com/seagenglobal
5k Members
Astellas Pharma
About Us:
Astellas Pharma US, Inc. is a U.S. affiliate of Tokyo-based Astellas Pharma Inc., a pharmaceutical conducting business in more than 70 countries around the world. Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the U.S. and around the world.
Website:
https://www.astellas.com/us
Representative:
Eric Lapham, Senior Access and Reimbursement Manager, Health Systems
Cell/Mobile: 732 245 4232
Eric.Lapham@astellas.com
Social Media:
Twitter at @AstellasUS
Facebook at www.facebook.com/AstellasUS
LinkedIn at www.linkedin.com/company/astellas-pharma-us.
Astellas Pharma US, Inc. is a U.S. affiliate of Tokyo-based Astellas Pharma Inc., a pharmaceutical conducting business in more than 70 countries around the world. Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the U.S. and around the world.
Website:
https://www.astellas.com/us
Representative:
Eric Lapham, Senior Access and Reimbursement Manager, Health Systems
Cell/Mobile: 732 245 4232
Eric.Lapham@astellas.com
Social Media:
Twitter at @AstellasUS
Facebook at www.facebook.com/AstellasUS
LinkedIn at www.linkedin.com/company/astellas-pharma-us.
Aveo
About Us:
AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. AVEO’s strategy is to focus its resources toward the development and commercialization of its product candidates in North America, while leveraging partnerships to do the same in other geographies. In March 2021, AVEO received FDA approval of FOTIVDA® (tivozanib). To learn more about FOTIVDA efficacy, safety, and relevant resources, visit our website at FOTIVDAHCP.com or click the link below.
Website:
https://www.aveooncology.com
Representative:
Jenny Passett – Oncology Account Manager
(716) 713-6708
jpassett@aveooncology.com
Aveo Oncology – 30 Winter Street, Boston, MA 02108
Social Media:
Twitter: https://twitter.com/aveooncology
LinkedIn: https://www.linkedin.com/company/54167?trk=tyah
AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. AVEO’s strategy is to focus its resources toward the development and commercialization of its product candidates in North America, while leveraging partnerships to do the same in other geographies. In March 2021, AVEO received FDA approval of FOTIVDA® (tivozanib). To learn more about FOTIVDA efficacy, safety, and relevant resources, visit our website at FOTIVDAHCP.com or click the link below.
Website:
https://www.aveooncology.com
Representative:
Jenny Passett – Oncology Account Manager
(716) 713-6708
jpassett@aveooncology.com
Aveo Oncology – 30 Winter Street, Boston, MA 02108
Social Media:
Twitter: https://twitter.com/aveooncology
LinkedIn: https://www.linkedin.com/company/54167?trk=tyah
Exelixis, Inc.
About us:
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines. To ensure you have the latest clinical data, including links to our pivotal trial publications, and important product information, visit our website.
Website:
https://www.exelixis.com
Representative:
Michael Nozzi
Senior Oncology Account Manager
570-357-1906
mnozzi@exelixis.com
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines. To ensure you have the latest clinical data, including links to our pivotal trial publications, and important product information, visit our website.
Website:
https://www.exelixis.com
Representative:
Michael Nozzi
Senior Oncology Account Manager
570-357-1906
mnozzi@exelixis.com
Kyowa Kirin
About us:
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we apply cutting-edge science and expertise in antibody research and engineering to address the needs of patients and society across multiple therapeutic areas, including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four global regions – Japan, Asia Pacific, North America and EMEA/International – we are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity, and a drive to advance innovations that have a profound impact on patients. You can learn more about Kyowa Kirin North America at: https://kkna.kyowakirin.com.
Website:
https://kkna.kyowakirin.com
Representative:
Nicole Lesterick, Oncology Account Manager, Kyowa Kirin, Inc., 135 US-202, Bedminster, NJ 07921
Social Media
LinkedIn: Kyowa Kirin, Inc.- U.S.
Twitter: @KyowaKirin_US
YouTube: Kyowa Kirin North America
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we apply cutting-edge science and expertise in antibody research and engineering to address the needs of patients and society across multiple therapeutic areas, including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four global regions – Japan, Asia Pacific, North America and EMEA/International – we are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity, and a drive to advance innovations that have a profound impact on patients. You can learn more about Kyowa Kirin North America at: https://kkna.kyowakirin.com.
Website:
https://kkna.kyowakirin.com
Representative:
Nicole Lesterick, Oncology Account Manager, Kyowa Kirin, Inc., 135 US-202, Bedminster, NJ 07921
Social Media
LinkedIn: Kyowa Kirin, Inc.- U.S.
Twitter: @KyowaKirin_US
YouTube: Kyowa Kirin North America
Natera
About us:
Natera is a pioneer and global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, cancer researchers, biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com. Follow Natera on LinkedIn.
Website:
www.natera.com/oncology
Representatives:
Facebook: https://www.facebook.com/NateraGenetics/
Twitter: https://twitter.com/NateraOncology
LinkedIn: https://www.linkedin.com/company/natera
YouTube: https://www.youtube.com/watch?v=NnmuCPnr9vM
Natera is a pioneer and global leader in cell-free DNA testing. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health. Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, cancer researchers, biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. For more information, visit natera.com. Follow Natera on LinkedIn.
Website:
www.natera.com/oncology
Representatives:
- Mike Weber, Clinical Oncology Specialist, Greater Philadelphia: mweber@natera.com (215) 630-6505
- Jonathan Liess, Clinical Oncology Specialist, Greater Allentown: jliess@natera.com (215) 279-1033
- Cynthia Los, Clinical Oncology Specialist, Southeastern PA, DE & MD: clos@natera.com (443) 622-7072
- Lydia Hammond, Clinical Oncology Specialist, Greater Harrisburg: lhammond@natera.com (507) 261-9537
- Tiffany Stein, Clinical Oncology Specialist, Greater Pittsburgh: tstein@natera.com (412) 980-0763
Facebook: https://www.facebook.com/NateraGenetics/
Twitter: https://twitter.com/NateraOncology
LinkedIn: https://www.linkedin.com/company/natera
YouTube: https://www.youtube.com/watch?v=NnmuCPnr9vM
Pfizer Oncology
Representatives:
Sue Sproat, CPC, CHONC, CMR, Field Reimbursement Manager - MD, DC, DE, PA
410-627-0807 (cell) | 484-323-7995 (fax)
susan.r.sproat@pfizer.com
Sue Sproat, CPC, CHONC, CMR, Field Reimbursement Manager - MD, DC, DE, PA
410-627-0807 (cell) | 484-323-7995 (fax)
susan.r.sproat@pfizer.com
Sanofi Genzyme
About us:
Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at www.sanofigenzyme.com.
Website:
www.sanofigenzyme.com
Representatives:
Nanette Rutherford, Field Reimbursement Manager
724-708-6495
nanette.rutherford@sanofi.com
Social Media:
Facebook: https://www.facebook.com/SanofiGenzyme/
LinkedIn: https://www.linkedin.com/company/sanofigenzyme/
Twitter: https://twitter.com/SanofiGenzyme
CareASSIST Patient Support Information:
Advertisement
About CareASSIST
Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at www.sanofigenzyme.com.
Website:
www.sanofigenzyme.com
Representatives:
Nanette Rutherford, Field Reimbursement Manager
724-708-6495
nanette.rutherford@sanofi.com
Social Media:
Facebook: https://www.facebook.com/SanofiGenzyme/
LinkedIn: https://www.linkedin.com/company/sanofigenzyme/
Twitter: https://twitter.com/SanofiGenzyme
CareASSIST Patient Support Information:
Advertisement
About CareASSIST
